Dr. Cambou is a junior investigator with broad interests in HIV and HPV co-infection, ranging from epidemiology to clinical trials. Dr. Cambou received a BA in Molecular and Cell Biology from the University of California (UC) Berkeley. During medical school at UC Los Angeles (UCLA), she received a ten-month, NIH-funded research grant to evaluate HIV and HPV epidemiology in women in Rio de Janeiro, Brazil. Her primary project evaluated anal high-risk HPV (HR-HPV) prevalence, and factors associated with abnormal anal cytology in a large cohort of women living with HIV. This research informed the UNAIDS reference on HPV, HIV and cervical/anal cancer. After medical school, she completed training in Social Internal Medicine at Montefiore Medical Center in New York. Dr. Cambou returned to UCLA for her Infectious Diseases fellowship, where she was recognized for her productivity as a researcher, and received the Specialty Training and Advanced Research (STAR) award to pursue a PhD at the Fielding School of Public Health. Dr. Cambou works with Dr. Landovitz at the UCLA Center for Clinical AIDS Research and Education (CARE), and has served as one of the site investigators for the ANCHOR study since 2020.
El estudio ANCHOR se ha interrumpido debido a la alta tasa de éxito del tratamiento. Tratar lesiones precursoras de cáncer anal reduce el riesgo de cáncer en personas que viven con VIH. Haga clic aquí para ver el comunicado de prensa de UCSF. Comuníquese con su clínica de ANCHOR si tiene cualquier pregunta o duda. Muchas gracias.